Loading
Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Sunitinib Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT) | 50 mg once daily, 4 weeks on / 2 weeks off (37.5 mg continuous in NET) | Oral | D1-28 |
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.